Puneet Souda
Stock Analyst at Leerink Partners
(2.02)
# 3,090
Out of 5,245 analysts
199
Total ratings
48.75%
Success rate
-0.46%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMR Alamar Biosciences | Initiates: Outperform | $35 | $20.06 | +74.48% | 1 | May 12, 2026 | |
| TWST Twist Bioscience | Upgrades: Outperform | $70 | $60.57 | +15.57% | 7 | May 5, 2026 | |
| NEO NeoGenomics | Upgrades: Outperform | $12 → $25 | $9.23 | +170.86% | 11 | Apr 29, 2026 | |
| GH Guardant Health | Maintains: Outperform | $170 → $180 | $118.95 | +51.32% | 8 | Feb 20, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $448.28 | +29.38% | 20 | Oct 22, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $14.00 | +14.29% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $7.28 | +64.84% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $2.69 | +197.40% | 12 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $3.81 | +451.18% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $45.03 | -11.17% | 14 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $150 | $203.19 | -26.18% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $342.37 | +9.53% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $20.15 | +73.70% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $114.96 | +26.13% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $172.00 | +74.42% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $144.41 | +73.12% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $48.21 | +128.17% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $115.06 | +73.82% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $5.20 | +246.15% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $2.65 | +126.42% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $45.69 | +90.41% | 13 | May 5, 2022 |
Alamar Biosciences
May 12, 2026
Initiates: Outperform
Price Target: $35
Current: $20.06
Upside: +74.48%
Twist Bioscience
May 5, 2026
Upgrades: Outperform
Price Target: $70
Current: $60.57
Upside: +15.57%
NeoGenomics
Apr 29, 2026
Upgrades: Outperform
Price Target: $12 → $25
Current: $9.23
Upside: +170.86%
Guardant Health
Feb 20, 2026
Maintains: Outperform
Price Target: $170 → $180
Current: $118.95
Upside: +51.32%
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $448.28
Upside: +29.38%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $14.00
Upside: +14.29%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $7.28
Upside: +64.84%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $2.69
Upside: +197.40%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $3.81
Upside: +451.18%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $45.03
Upside: -11.17%
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $203.19
Upside: -26.18%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $342.37
Upside: +9.53%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $20.15
Upside: +73.70%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $114.96
Upside: +26.13%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $172.00
Upside: +74.42%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $144.41
Upside: +73.12%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $48.21
Upside: +128.17%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $115.06
Upside: +73.82%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $5.20
Upside: +246.15%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $2.65
Upside: +126.42%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $45.69
Upside: +90.41%